The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors ...
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...
Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers ...
The FDA green-lit four drugs last year without any U.S. trial participants, according to CDER’s drug trials snapshot report, which summarizes the various demographics of clinical trials for approved ...
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune ...
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing ...
CEOs can make or break a company. And new leaders at three of pharma’s largest drugmakers are taking over with little room for error. All three leaders took the ...
As patent protection for the cancer juggernaut Keytruda approaches a critical juncture, Merck & Co. won’t give up market share without a fight. The company revealed this week that a subcutaneous ...
Last year, Bristol Myers Squibb put a spotlight on the kind of cash that comes with pharma’s conviction in a new oncology strategy. The drugmaker agreed to pay BioNTech $1.5 billion upfront and ...
Attempting to bring new medicines to market is an inherently risky endeavor, with sponsors ultimately failing more than 90% of the time. But rare disease development is even harder; there are fewer ...
Welcome to today’s Biotech Spotlight, a series featuring companies that are creating breakthrough technologies and products. Today, we’re looking at Anokion, a Swiss biotech pioneering a vaccine to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results